Hyperfine, Inc. (HYPR) Fair Value 2026

HYPR · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.8 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-08-28, Hyperfine, Inc. (HYPR) trades at $0.83. QOC: 6.8/10. Value Trap Risk: 26/100 (LOW). 1/13 models active.

Key Facts

Ticker
HYPR
Price
$0.83
Quality Score
6.8/10
Value Trap Risk
26/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give HYPR?

1 Intrinsic Value Models vs. Current Price ($0.83)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · High Conviction
 $0.65 -21.7%

All Models Active

All 1 models are displayed above.

What Is Hyperfine, Inc. (HYPR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Hyperfine, Inc.'s intrinsic value is estimated at $0.65, suggesting the stock is overvalued at its current price of $0.83. With 1 out of 1 models flagging downside (-21.7% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About HYPR?

1 of 13 models are currently active for HYPR. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does HYPR Rank in Medical Devices?

Among 159 Medical Devices stocks, HYPR ranks #58 by Quality of Company score. CirclFi's QOC score of 6.8/10 evaluates 32 fundamental signals. A score of 6.8 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

As a biopharma enterprise, Hyperfine, Inc. operates in a sector where biosimilar competition timeline is a critical driver of valuation. Investors evaluating HYPR should weigh these sector-specific dynamics alongside our model-derived fair values.

Is HYPR a Value Trap?

CirclFi's Value Trap algorithm assigns HYPR a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Hyperfine, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Hyperfine, Inc.'s fundamental quality profile registers 6.8/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every HYPR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across HYPR's 1 active models, average confidence is 51%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Hyperfine, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

SENSSenseonics Holdings, Inc.QOC 6.8PROFProfound Medical Corp.QOC 6.8NEOGNeogen CorporationQOC 6.9GKOSGlaukos CorporationQOC 6.7ATECAlphatec Holdings, Inc.QOC 6.9RCELAVITA Medical, Inc.QOC 6.7OWLTOwlet, Inc.QOC 5.8POASPhaos Technology Holdings (CaymQOC 4.5INMDInMode Ltd.QOC 8.5IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: SENS · PROF · NEOG · GKOS · ATEC · RCEL · OWLT · POAS · INMD · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to HYPR?

7 companies across all industries closest to HYPR’s Quality of Company score of 6.8/10.

TLSTelos CorporationQOC 6.8GNKGenco Shipping & Trading LimitedQOC 6.8CHUCCharlie's Holdings, Inc.QOC 6.8LIFDLFTD Partners Inc.QOC 6.8DUOTDuos Technologies Group, Inc.QOC 6.8OISOil States International, Inc.QOC 6.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: TLS · GNK · CHUC · LIFD · DUOT · OIS · NVDA

Where Does HYPR Sit in CirclFi's Medical Devices Rankings?

HYPR is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Hyperfine, Inc.’s Valuation?

What is Hyperfine, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Hyperfine, Inc. (HYPR). The Quality of Company score is 6.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is HYPR overvalued or undervalued right now?

At $0.83, 0 of 1 active models suggest HYPR may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Hyperfine, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 6.8 mean for HYPR?

Hyperfine, Inc.'s QOC of 6.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on HYPR?

CirclFi analyzes HYPR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is HYPR a value trap in 2026?

Hyperfine, Inc.'s Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Hyperfine, Inc. (HYPR) a Quality of Company score of 6.8/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/HYPR/ · Methodology
Primary sources for this HYPR valuation
  • Financial statements: Hyperfine, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001833769) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for HYPR as of ; valuations recomputed .